Fc Receptor is Involved in Nk Cell Functional Anergy Induced by Miapaca2 Tumor Cell Line

References

• Abrams SI, Brahmi Z. 1988. Target cell directed NK inactivation. Concomitant loss of NK and antibody-dependent cellular cytotoxicity activities. J Immunol. 140:2090–95.
   PubMed Web of Science ®Google Scholar
• Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O’Shea JJ, Shevach EM. 2008. CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-β–dependent manner. J Exp Med. 205:1975–81.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, et al. 2016. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 531:47–52.
   PubMed Web of Science ®Google Scholar
• Bassani B, Baci D, Gallazzi M, Poggi A, Bruno A, Mortara L. 2019. Natural killer cells as key players of tumor progression and angiogenesis: old and novel tools to divert their pro-tumor activities into potent anti-tumor effects. Cancers (Basel) 11: Pii:. E461. doi:https://doi.org/10.3390/cancers11040461
   Google Scholar
• Belyaev NN, Abramova VA. 2014. Transmission of “split anergy” from tumor infiltrating to peripheral NK cells in a manner similar to “infectious tolerance”. Med Hypotheses. 82:129–33.
   PubMed Web of Science ®Google Scholar
• Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G. 2008. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16- cells and display an impaired capability to kill tumor cells. Cancer. 112:863–75.
   PubMed Web of Science ®Google Scholar
• Castro-Dopico T, Clatworthy MR. 2016. Fcγ receptors in solid organ transplantation. Curr Transpl Rep. 3:284–93.
   PubMedGoogle Scholar
• Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM. 2012. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother. 35:629–40.
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N, Toi M. 2009. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother. 63:703–06.
   PubMed Web of Science ®Google Scholar
• Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, Gervois N, Allard M, Bercovici N, Avril MF, Caignard A. 2011. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res. 17:2628–37.
   PubMed Web of Science ®Google Scholar
• Funa K, Nilsson B, Jacobsson G, Alm GV. 1984. Decreased natural killer cell activity and interferon production by leucocytes in patients with adenocarcinoma of the pancreas. Br J Cancer. 50:231–33.
   PubMed Web of Science ®Google Scholar
• Heiskala M, Ylikorkala O, Timonen T. 1987. Inhibition of human natural killer activity by monolayers of primary cell cultures. Nat Immun Cell Growth Regul. 6:1–11.
   PubMedGoogle Scholar
• Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, et al. 2018. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 128:4654–68.
   PubMed Web of Science ®Google Scholar
• Hu S, Yang J, Shangguan J, Eresen A, Li Y, Ma Q, Yaghmai V, Velichko Y, Hu C, Zhang Z. 2019. Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a KrasLSL-G12Dp53LSL-R172HPdx1-Cre mouse model. Am J Cancer Res. 9:1757–65.
   PubMed Web of Science ®Google Scholar
• Iannone F, Porzia A, Peruzzi G, Birarelli P, Milana B, Sacco L, Dinatale G, Peparini N, Prezioso G, Battella S, et al. 2015. Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function. Pancreas. 44:386–93.
   PubMed Web of Science ®Google Scholar
• Jewett A, Arasteh A, Tseng HC, Behel A, Arasteh H, Yang W, Cacalano NA, Paranjpe A. 2010. Strategies to rescue mesenchymal stem cells (MSCs) and dental pulp stem cells (DPSCs) from NK cell mediated cytotoxicity. PLoS One. 5:e9874.
   PubMed Web of Science ®Google Scholar
• Jewett A, Bonavida B. 1995. Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cell Immunol. 160:91–97.
   PubMed Web of Science ®Google Scholar
• Jewett A, Bonavida B. 1996. Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol. 56:907–15.
   Google Scholar
• Jewett A, Cavalcanti M, Bonavida B. 1997. Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol. 159:4815–22.
   PubMed Web of Science ®Google Scholar
• Jewett A, Man YG, Tseng HC. 2013. Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of tissues. J Cancer. 4:12–24.
   PubMed Web of Science ®Google Scholar
• Jewett A, Teruel A, Romero M, Head C, Cacalano N. 2008. Rapid and potent induction of cell death and loss of NK cell cytotoxicity against oral tumors by F(ab’)2 fragment of anti-CD16 antibody. Cancer Immunol Immunother. 57:1053–66.
   PubMed Web of Science ®Google Scholar
• Jewett A, Tseng HC. 2012. Potential rescue, survival and differentiation of cancer stem cells and primary non-transformed stem cells by monocyte-induced split anergy in natural killer cells. Cancer Immunol Immunother. 61:265–74.
   PubMed Web of Science ®Google Scholar
• Jun E, Song AY, Choi JW, Lee HH, Kim MY, Ko DH, Kang HJ, Kim SW, Bryceson Y, Kim SC, et al. 2019. Progressive impairment of NK cell cytotoxic degranulation is associated with TGF-β1 deregulation and disease progression in pancreatic cancer. Front Immunol. 10:1354.
   PubMed Web of Science ®Google Scholar
• Kali A, Ostapchuk YO, Belyaev NN. 2017. TNF-alpha and TGF-beta-1 synergistically increase the cancer stem cell properties of MiaPaCa2 cells. Oncol Lett. 14:4647–58.
   PubMed Web of Science ®Google Scholar
• Karakhanova S, Ryschich E, Mosl B, Harig S, Jager D, Schmidt J, Hartwig W, Werner J, Bazhin AV. 2015. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Br J Cancer. 112:1027–36.
   PubMed Web of Science ®Google Scholar
• Kuss I, Saito T, Johnson JT, Whiteside TL. 1999. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res. 5:329–34.
   PubMed Web of Science ®Google Scholar
• Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. 1996. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res. 2:161–73.
   PubMed Web of Science ®Google Scholar
• Le Maux Chansac B, Moretta A, Vergnon I, Opolon P, Lécluse Y, Grunenwald D, Kubin M, Soria JC, Chouaib S, Mami-Chouaib F. 2005. NK cells infiltrating a MHC Class Ideficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol. 175:5790–98.
   PubMed Web of Science ®Google Scholar
• Levy EM, Roberti MP, Mordoh J. 2011. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotech. 2011:676198.
   PubMedGoogle Scholar
• Li M, Xia P, Du Y, Liu S, Huang G, Chen J, Zhang H, Hou N, Cheng X, Zhou L, et al. 2014. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling. J Biol Chem. 289:17647–57.
   PubMed Web of Science ®Google Scholar
• Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, Im K, Han Y, Kwon W, Kim SW, et al. 2019. Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells in pancreatic cancer patients. Front Immunol. 10:496.
   PubMed Web of Science ®Google Scholar
• Liu H, Shalev I, Manuel J, He W, Leung E, Crookshank J, Liu MF, Diao J, Cattral M, Clark DA, et al. 2008. The FGL2-FcgammaRIIB pathway: a novel mechanism leading to immunosuppression. Eur J Immunol. 38:3114–26.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang H, Li M, Hu D, Li C, Ge B, Jin B, Fan Z. 2013. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 20:456–64.
   PubMed Web of Science ®Google Scholar
• Maccalli C, Parmiani G, Ferrone S. 2017. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: implications for the Clinical Success of Immunotherapy. Immunol Invest. 46:221–38.
   PubMed Web of Science ®Google Scholar
• Magister Š, Tseng HC, Bui VT, Kos J, Jewett A. 2015. Regulation of split anergy in natural killer cells by inhibition of cathepsins C and H and cystatin F. Oncotarget. 8:22310–27.
   Google Scholar
• Mammesier E, Sylvain A, Thibult M-L, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, et al. 2011. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 121:3609–22.
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Okada Y, Yoshida O, Bonavida B. 1996. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer. Cancer Biother Radiopharm. 11:385–91.
   PubMed Web of Science ®Google Scholar
• Oh E, Min B, Li Y, Lian CY, Hong JW, Park G-M, Yang B, Cho SY, Hwang YK, Yun C-O. 2019. Cryopreserved human Natural Killer Cells exhibit potent antitumor efficacy against orthotopic pancreatic cancer through efficient tumor-homing and cytolytic ability. Cancers (Basel). 11:966.
   Web of Science ®Google Scholar
• Ostapchuk YO, Aktas Cetin E, Perfilyeva YV, Yilmaz A, Skiba YA, Chirkin AP, Omarbaeva NA, Talaeva SG, Belyaev NN, Deniz G. 2015. Peripheral blood NK cells expressing HLA-G, IL-10 and TGF-ß in healthy donors and breast cancer patients. Cell Immunol. 298:37–46.
   PubMed Web of Science ®Google Scholar
• Peng YP, Zhang JJ, Liang WB, Tu M, Lu ZP, Wei JS, Jiang KR, Gao WT, Wu JL, Xu ZK, et al. 2014. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. BMC Cancer. 14:738.
   PubMed Web of Science ®Google Scholar
• Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, Jiang KR, Wu JL, Gao WT, Li Q, et al. 2012. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med. 11:262.
   Web of Science ®Google Scholar
• Pesce S, Greppi M, Grossi F, Del Zotto G, Moretta L, Sivori S, Genova C, Marcenaro E. 2019. PD/1-PD-Ls Checkpoint: insight on the Potential Role of NK Cells. Front Immunol. 10:1242.
   PubMed Web of Science ®Google Scholar
• Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, Alva JA, Walter G, Head C, Ishikawa TO, et al. 2010. Increased lysis of stem cells but not their differentiated cells by natural killer cells; dedifferentiation or reprogramming activates NK cells. PLoS One. 5:e11590.
   PubMed Web of Science ®Google Scholar
• Tseng HC, Cacalano N, Jewett A. 2015. Split anergized natural killer cells halt inflammation by inducing stem cell differentiation, resistance to NK cell cytotoxicity and prevention of cytokine and chemokine secretion. Oncotarget. 6:8947–59.
   PubMedGoogle Scholar
• Viel S, Charrier E, Marcais A, Rouzaire P, Bienvenu J, Karlin L, Salles G, Walzer T. 2013. Monitoring NK cell activity in patients with hematological malignancies. Oncoimmunology. 2:e26011.
   PubMed Web of Science ®Google Scholar
• Wang KS, Frank DA, Ritz J. 2000. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood. 95:3183–90.
   PubMed Web of Science ®Google Scholar
• White D, Jones DB, Cooke T, Kirkham N. 1982. Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease. Br J Cancer. 46:611–16.
   PubMed Web of Science ®Google Scholar
• Xu YF, Lu Y, Cheng H, Shi S, Xu J, Long J, Liu L, Yu X. 2014. Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. Pancreatology. 14:295–301.
   PubMed Web of Science ®Google Scholar
• Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li S. 2015. FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. J Natl Cancer Inst. 107:pii:djv137.
   Google Scholar
• Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, et al. 2019. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun. 10:448.
   PubMed Web of Science ®Google Scholar
• Yang M, Zhang Z, Chen J, Xu M, Huang J, Wang M, Li W, Wan X, Yuen M-F, Luo X, et al. 2019. Soluble fibrinogen-like protein 2 promotes the growth of hepatocellular carcinoma via attenuating dendritic cell-mediated cytotoxic T cell activity. J Exp Clin Cancer Res. 38(1):351.
   PubMed Web of Science ®Google Scholar
• Yuwaraj S, Ding J, Liu M, Marsden PA, Levy GA. 2001. Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin: a novel human procoagulant. Genomics. 71:330–38.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang L, Zha H, Yang F, Hu C, Chen L, Guo B, Zhu B. 2017. Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer. Int J Biol Sci. 13:804–14.
   PubMed Web of Science ®Google Scholar